Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 6, 2022

Details for Patent: 9,907,780

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,907,780 protect, and when does it expire?

Patent 9,907,780 protects SILENOR and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 9,907,780
Title:Low-dose doxepin formulations and methods of making and using the same
Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
Inventor(s): Schioppi; Luigi (Escondido, CA), Dorsey; Brian Talmadge (Encinitas, CA), Skinner; Michael (San Diego, CA), Carter; John (Keswick, CA), Mansbach; Robert (San Diego, CA), Jochelson; Philip (San Diego, CA), Rogowski; Roberta L. (Rancho Santa Fe, CA), Casseday; Cara Baron (San Diego, CA), Perry; Meredith (El Cajon, CA), Knox; Bryan (San Diego, CA)
Assignee: Pernix Sleep, Inc. (Morristown, NJ)
Application Number:15/394,912
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,907,780
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 9,907,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,907,780

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2721133 See Plans and Pricing
European Patent Office 2148659 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008128115 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.